Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone as Adjunct to Thrombectomy in Acute Ischemic Stroke
NCT07202143Phase 3Recruiting
- Sponsor
- Yiling Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Methylprednisolone with Placebo (2 arms). Primary endpoint: All-cause mortality at 90 days. Started Sep 2025; status: recruiting.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07202143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202143.